LCID
Lucid Group, Inc.
LCID has the edge over PHM overall, supported by stronger valuation and stronger fundamentals.
PHM
PulteGroup, Inc.
PHM has lower modeled downside risk, despite its lower overall score.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
PHM Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Stable | |
| Strong |
PHM's balance sheet is currently strong, and its profitability and cash flow are stable, but its revenue is under pressure.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
PHM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.8x | $54.71 | -57% |
| Fair | 8.8x | $82.04 | -35% |
| Expensive | 11x | $99.83 | -21% |
| Current | 14x | $127 | — |
| Forward | 14x | $127 | — |
Historical ranges are pointers, not guarantees.
PHM's PE is in its expensive range at 13.6x. On analysts' estimates for next year's earnings, today's price would be 13.7x.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
PHM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect PHM's profitability to weaken, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
PHM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.29 | -0.7% |
| Q3 2026 | $9.36 | -28% |
| Q2 2026 | $9.79 | -27% |
| Q1 2026 | $10.34 | -27% |
| Q4 2025 | $11.12 | -24% |
| Q3 2025 | $12.97 | -4.2% |
| Q2 2025 | $13.36 | +2.1% |
| Q1 2025 | $14.16 | +14% |
| Q4 2024 | $14.69 | +25% |
PHM has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over PHM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
PHM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4B | -9.8% |
| Q2 2026 | $4B | -9.6% |
| Q1 2026 | $3.4B | -12% |
| Q4 2025 | $4.6B | -6.3% |
| Q3 2025 | $4.4B | -1.6% |
| Q2 2025 | $4.4B | -4.3% |
| Q1 2025 | $3.9B | -1.4% |
| Q4 2024 | $4.9B | +15% |
PHM's revenue has slid since its 2022 peak: $4B last quarter, down 9.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -1.7 points |
| Q2 2026 | 16% | -2.7 points |
| Q1 2026 | 13% | -4.3 points |
| Q4 2025 | 14% | -9.8 points |
| Q3 2025 | 17% | -2.8 points |
| Q2 2025 | 18% | -4.5 points |
| Q1 2025 | 18% | -4.5 points |
| Q4 2024 | 24% | +2 points |
PHM has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
PHM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $437.2M | -33% |
| Q2 2026 | -$12.9M | -105% |
| Q1 2026 | $134.4M | +28% |
| Q4 2025 | $739.8M | +36% |
| Q3 2025 | $651.1M | +56% |
| Q2 2025 | $253M | -35% |
| Q1 2025 | $104.6M | -51% |
| Q4 2024 | $543.1M | +106% |
PHM has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
PHM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -2.7M shares |
| 1 year | -5.2% | -10.3M shares |
| 3 years | -14% | -31.8M shares |
| 5 years | -27% | -71.1M shares |
| Available history | -31% | -83.6M shares |
PHM has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $350.4M |
| Q2 2026 | $373M |
| Q1 2026 | $308.2M |
| Q4 2025 | $300M |
| Q3 2025 | $300M |
| Q2 2025 | $300M |
| Q1 2025 | $300M |
| Q4 2024 | $320M |
PHM spent $1.3B buying back its own shares over the past year, up 9.1% from the year before.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PHM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.2x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | 0.0x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | -0.4x | Net Cash |
PHM's net debt is less than a year of its operating earnings (EBITDA).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
PHM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 66.1 | Neutral |
PHM's weekly RSI is 53 (neutral) and its Stochastic is 66 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
PHM PE vs Consumer Cyclical Sector
| Metric | PHM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 18x | 25% below |
| PE % | 99 | 47 | 52 pts above |
PHM is trading at 14x earnings, a 25% discount to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
PHM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $120.8 | 5% above |
| 20 week MA | $124.3 | 2.1% above |
| 50 week MA | $124.4 | 2% above |
| 100 week MA | $118.8 | 6.8% above |
| 200 week MA | $107.7 | 18% above |
PHM has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
PHM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $38.8 | $45.2 | +17% |
| 2021 | $45.2 | $54.7 | +21% |
| 2022 | $54.7 | $45.8 | -16% |
| 2023 | $45.8 | $103.2 | +125% |
| 2024 | $103.2 | $109.5 | +6.1% |
| 2025 | $109.5 | $119.2 | +8.8% |
| 2026 YTD | $119.2 | $126.9 | +6.5% |
PHM has the edge over LCID on returns for 2026, with the stronger performance.